

Anders Erik Astrup Dahm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9325112/publications.pdf>

Version: 2024-02-01

25
papers

658
citations

840119

11
h-index

580395

25
g-index

26
all docs

26
docs citations

26
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients â€“ 30 months followâ€“up. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1166-1181.	1.9	23
2	Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 5127.	1.6	11
3	Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1729-1737.	1.9	5
4	Bias in animal studies of estrogen effects on cardiovascular disease: A systematic review and metaâ€“analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12507.	1.0	3
5	Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?. <i>Blood Advances</i> , 2021, 5, 2516-2517.	2.5	1
6	Cancer and Thrombosis: New Treatments, New Challenges. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 41.	1.3	4
7	Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis. <i>Blood Advances</i> , 2020, 4, 5002-5010.	2.5	4
8	Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. <i>Thrombosis Research</i> , 2020, 196, 238-244.	0.8	5
9	Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 105.	0.4	2
10	Safety of Dâ€“dimer testing as a standâ€“alone test for the exclusion of deep vein thrombosis as compared with other strategies. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2471-2481.	1.9	20
11	Normalization of disrupted clock gene expression in males with tetraplegia: a crossover randomized placebo-controlled trial of melatonin supplementation. <i>Spinal Cord</i> , 2018, 56, 1076-1083.	0.9	9
12	PAN3â€“PSMA2 fusion resulting from a novel t(7;13)(p14;q12) chromosome translocation in a myelodysplastic syndrome that evolved into acute myeloid leukemia. <i>Experimental Hematology and Oncology</i> , 2018, 7, 7.	2.0	8
13	Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. <i>PLoS ONE</i> , 2017, 12, e0176527.	1.1	10
14	A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. <i>Thrombosis Research</i> , 2017, 157, 111-116.	0.8	21
15	Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, placebo-controlled cross-over study of melatonin. <i>Spinal Cord</i> , 2015, 53, 285-290.	0.9	10
16	Genetic variations in the annexin A5 gene and the risk of pregnancyâ€“related venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 409-413.	1.9	10
17	Interaction between tissue factor pathway inhibitor and factor V levels on the risk of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1130-1132.	1.9	7
18	The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 393-395.	1.9	36

#	ARTICLE	IF	CITATIONS
19	Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 346-351.	1.9	63
20	Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 346-351.	1.9	24
21	The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 393-395.	1.9	16
22	Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. <i>British Journal of Haematology</i> , 2006, 132, 333-338.	1.2	14
23	A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 651-658.	1.9	39
24	Determinants of the APTT- and ETP-based APC sensitivity tests. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1488-1494.	1.9	87
25	Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. <i>Blood</i> , 2003, 101, 4387-4392.	0.6	222